# [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

Source: https://nuclide.cc/trials/nct07702292/  
Nuclide record `nct07702292` (Trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of [68Ga]BED003 in colorectal cancer, ovarian cancer, gastric & gastro-oesophageal junction cancer and pancreatic ductal adenocarcinoma, run by Blue Earth Diagnostics, now recruiting.

## Summary

[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications is a phase 2 interventional study registered as NCT07702292 by Blue Earth Diagnostics, with 71 participants planned, started 2026-06-30 and due to reach its primary completion in 2028-02. Interventions recorded: [68Ga]BED003.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07702292
- Phase: 2
- Setting: A Phase 2 Study of [68Ga]BED003 for PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
- Sponsor: Blue Earth Diagnostics
- Enrolled: 71

## Sources

- ClinicalTrials.gov NCT07702292: https://clinicaltrials.gov/study/NCT07702292

## Connected records

- isotopes: [Gallium-68](https://nuclide.cc/isotopes/ga-68/)
- companies: [Blue Earth Diagnostics (Bracco)](https://nuclide.cc/companies/blue-earth-diagnostics/)

---
JSON: https://nuclide.cc/api/v1/entities/nct07702292.json